Diagnosis and Management of Infantile Hemangioma

Table C. Summary of evidence in studies addressing effectiveness of pharmacologic interventions (continued)
Intervention
Type/Number of
Studies (Total N
Participants)
Key Outcome(s)
Strength of
Evidence
(SOE) Grade
Findings
Beta-Blockers
(continued)
Oral nadolol
Cohort studies: 1 (19)
Oral atenolol
RCT: 1 (23)
Cohort studies: 1 (58)
Significant and minor
harms (significant:
hypotension,
bradycardia,
bronchospasm,
hypoglycemia; minor:
cold extremities,
diarrhea, sleep
changes)
Significant and minor
harms (significant:
hypotension; minor:
cold extremities,
diarrhea, sleep
changes)
Insufficient
Insufficient
Harms reported in 20% to 50% of children.
Insufficient SOE due to single, small study with high limitations.
Harms reported ranged from 3% to 27% in 2 small studies
Insufficient SOE due to high study limitations and few studies.
BCI = Bayesian credible interval; IH = infantile hemangioma; PDL= pulse dye laser; RCT = randomized controlled trial; SOE = strength of evidence
ES-23